FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1534-1535 May 18, 2000 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Richard A. Rudick and Donald E. Goodkin. 574 pp. London, Martin Dunitz, 1999. £79.95. ISBN 1-85317-812-8.

It was not long ago that the combination of the words "therapeutics" and "multiple sclerosis" verged on the oxymoronic. If there are investigators who still have this point of view, they are not represented among the authors of the 40 chapters in this well-produced book. The many topics discussed include clinical research methods, outcome measures, and the fine details of magnetic resonance imaging and spectroscopy. It is a sign of the times that three chapters describe the process of drug approval in the United States, Canada, and Europe. The general stance of most of the authors is remarkably upbeat, perhaps . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.